AUDIENCED

Patient family develops app for improved adherence and clinical outcomes

Darron Goralsky, a physiotherapist with over 30 years of experience, is the Clinical Director and Founder of Melbourne TMJ and Facial Pain Centre. He leads a multidisciplinary team dedicated to treating jaw pain, facial pain, and headaches. Goralsky has observed a rise in musculoskeletal issues among younger populations, largely due to increased screen time and poor posture, trends that intensified during the COVID-19 pandemic. Emphasising technology integration and patient responsibility, he believes digital health solutions play a crucial role in improving adherence and outcomes for both patients and caregivers.

CASE STUDY: Transforming surgical waitlist into a ‘preparation list’

The DIAMONDS initiative aims to transform the surgical waitlist into a “preparation list,” enabling healthcare professionals to optimise patient care in the months leading up to elective surgery starting at pre-admission phase.

Patients are will be able to complete pre-admission forms online, receive timely updates, and access educational resources to ensure thorough preparation. This will allow staff to spend more time with patients.

Confronting picture of growing women’s health crisis in uterine cancers

Uterine cancers have become Australia’s fastest-growing women’s cancer, with incidence doubling over the past 25 years and projected to continue to surge. Without immediate action, more than 44,000 women are expected to be diagnosed by 2035, and 8,900 will lose their lives to the disease.

Released November 2025, Australia’s first State of the Nation: Uterine Cancers in Australia 2025 report by the Australia New Zealand Gynaecological Oncology Group (ANZGOG), reveals a confronting picture of a growing women’s health crisis that has gone largely unseen and one that now requires immediate, coordinated national action.

From refugee to receiving multiple accolades as a community pharmacist

Sara is an experienced pharmacist, community health advocate, and the Lead Pharmacist at Pharmacy 777 Pascoe Vale in Victoria. With over 20 years in the profession, Sara has played a significant role in advancing local healthcare delivery through clinical leadership, service development, and strong community partnerships.

30 years on, Viertel Foundation legacy continues

One of Australia’s largest charitable foundations, the Sylvia and Charles Viertel Charitable Foundation, is celebrating three decades of transforming Australian healthcare – with more than $90 million invested in medical research and a legacy of breakthroughs that are saving lives. Viertel Fellowships support some of Australia’s best and brightest researchers and clinicians, with 70 Fellowships awarded to date.

Systems genetics to determine risk of developing diabetes complications

Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).

Growing impact of blood cancer on women

According to the Leukaemia Foundation, blood cancer is one of the most urgent and under-recognised women’s health issues in Australia, with three times more Australian women diagnosed with blood cancer than ovarian and cervical cancer combined (Source: AIHW, Cancer Data in Australia, 2024).

Blood cancer has also emerged as the second most common cancer diagnosed in Australian women overall – behind only breast cancer – and the leading cancer amongst girls and women under the age of 30 (Source: AIHW, Cancer Data in Australia, 2024).

Pancreatic and lung cancers driven by mutations in the cancer gene KRAS

Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).

Biopsychosocial approaches to obsessive-compulsive, body image and eating disorders

Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.

Nanoparticles & microparticles to combat antimicrobial resistance

Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.

Scroll to top